The University of Southampton
University of Southampton Institutional Repository

Use of alpha-blockers and the risk of hip/femur fractures

Use of alpha-blockers and the risk of hip/femur fractures
Use of alpha-blockers and the risk of hip/femur fractures
Objective: To study the association between use of ?-blockers and risk of hip/femur fractures.
Design: Population-based case–control study.
Setting: General Practice Research Database.
Subjects: Cases were defined as men, aged 40 years and older with a first diagnosis for hip/femur fracture. Controls were matched 1 : 1 on gender, year of birth and general practitioner-practice.
Results: In all, 4571 cases and an equal number of controls were identified. Current use of ?-blockers (prazosin, doxazosin, indoramin, terazosin, alfuzosin and tamsulosin) was compared with non-use of ?-blockers. Current use of ?-blockers on the index date was associated with an increased risk of hip/femur fracture [adjusted odds ratio (OR) 1.9, 95% confidence interval (CI): 1.1–3.0] in the overall analysis. The effect was particularly strong for first prescriptions within a treatment episode (adjusted OR 5.1, 95% CI: 1.0–31.7) and during the first month of treatment (adjusted OR 4.1, 95% CI: 0.7–23.9). Stratification according to indication of use showed that current use of ?-blockers was not associated with hip/femur fracture in men with a diagnosis of benign prostatic hyperplasia (adjusted OR 1.0, 95% CI: 0.4–2.5), but was associated in men who used ?-blockers for cardiovascular disease (adjusted OR 2.8, 95% CI: 1.4–5.4).
Conclusion: Current use of ?-blockers was associated with an increased risk of hip/femur fracture and with the start of a new treatment episode. The effect seemed to be confined to patients who used ?-blockers for cardiovascular disease. Caution with respect to first-dose effects related to the initiation of a new episode of ?-blocker treatment is advised.
adrenergic alpha-antagonists, case–control studies, hip fractures, pharmacoepidemiology
0954-6820
548-554
Souverein, P.C.
44dfc72c-9a33-4ab8-bce5-574052a8dc18
Van Staa, T.P.
31b8bfb4-4e1b-4a48-a5a6-90ca601b94af
Egberts, A.C.G.
eb765fde-f548-4c1a-8683-5480573617d5
De la Rosette, J.J.M.C.H.
167dde63-8d79-4cdd-aa40-cbdc47a9f87e
Cooper, C.
e05f5612-b493-4273-9b71-9e0ce32bdad6
Leufkens, H.G.M.
04854167-bea6-4508-a8e2-aeb920a2d6b1
Souverein, P.C.
44dfc72c-9a33-4ab8-bce5-574052a8dc18
Van Staa, T.P.
31b8bfb4-4e1b-4a48-a5a6-90ca601b94af
Egberts, A.C.G.
eb765fde-f548-4c1a-8683-5480573617d5
De la Rosette, J.J.M.C.H.
167dde63-8d79-4cdd-aa40-cbdc47a9f87e
Cooper, C.
e05f5612-b493-4273-9b71-9e0ce32bdad6
Leufkens, H.G.M.
04854167-bea6-4508-a8e2-aeb920a2d6b1

Souverein, P.C., Van Staa, T.P., Egberts, A.C.G., De la Rosette, J.J.M.C.H., Cooper, C. and Leufkens, H.G.M. (2003) Use of alpha-blockers and the risk of hip/femur fractures. Journal of Internal Medicine, 254 (6), 548-554. (doi:10.1111/j.1365-2796.2003.01227.x).

Record type: Article

Abstract

Objective: To study the association between use of ?-blockers and risk of hip/femur fractures.
Design: Population-based case–control study.
Setting: General Practice Research Database.
Subjects: Cases were defined as men, aged 40 years and older with a first diagnosis for hip/femur fracture. Controls were matched 1 : 1 on gender, year of birth and general practitioner-practice.
Results: In all, 4571 cases and an equal number of controls were identified. Current use of ?-blockers (prazosin, doxazosin, indoramin, terazosin, alfuzosin and tamsulosin) was compared with non-use of ?-blockers. Current use of ?-blockers on the index date was associated with an increased risk of hip/femur fracture [adjusted odds ratio (OR) 1.9, 95% confidence interval (CI): 1.1–3.0] in the overall analysis. The effect was particularly strong for first prescriptions within a treatment episode (adjusted OR 5.1, 95% CI: 1.0–31.7) and during the first month of treatment (adjusted OR 4.1, 95% CI: 0.7–23.9). Stratification according to indication of use showed that current use of ?-blockers was not associated with hip/femur fracture in men with a diagnosis of benign prostatic hyperplasia (adjusted OR 1.0, 95% CI: 0.4–2.5), but was associated in men who used ?-blockers for cardiovascular disease (adjusted OR 2.8, 95% CI: 1.4–5.4).
Conclusion: Current use of ?-blockers was associated with an increased risk of hip/femur fracture and with the start of a new treatment episode. The effect seemed to be confined to patients who used ?-blockers for cardiovascular disease. Caution with respect to first-dose effects related to the initiation of a new episode of ?-blocker treatment is advised.

This record has no associated files available for download.

More information

Published date: 2003
Keywords: adrenergic alpha-antagonists, case–control studies, hip fractures, pharmacoepidemiology

Identifiers

Local EPrints ID: 25991
URI: http://eprints.soton.ac.uk/id/eprint/25991
ISSN: 0954-6820
PURE UUID: 0d7c3500-06c2-49e9-91e2-73d41ec18fff
ORCID for C. Cooper: ORCID iD orcid.org/0000-0003-3510-0709

Catalogue record

Date deposited: 24 Apr 2006
Last modified: 18 Mar 2024 02:44

Export record

Altmetrics

Contributors

Author: P.C. Souverein
Author: T.P. Van Staa
Author: A.C.G. Egberts
Author: J.J.M.C.H. De la Rosette
Author: C. Cooper ORCID iD
Author: H.G.M. Leufkens

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×